Navigation Links
Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
Date:8/8/2008

factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

Halozyme Contact Media Contact

Robert H. Uhl Karen Sparks / Joleen Schultz

Senior Director, Investor Relations Mentus

(858) 704-8264 (858) 455-5500, x275/x215

ruhl@halozyme.com karen@mentus.com

jschultz@mentus.com

HALOZYME THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - UNAUDITED

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2008 AND 2007

Three Months Ended Six Months Ended

June 30, June 30,

2008 2007 2008 2007

REVENUES:

Revenue under

collaborative

agreements $1,351,492 $539,434 $3,015,572 $1,162,563

Product sales 82,727 169,082 224,165 356,168

Total Revenues 1,434,219 708,516 3,239,737 1,518,731

OPERATING EXPENSES:

Cost of product

sales 37,126 75,518 74,316 151,746

Research and

development 8,925,488 4,083,885 17,369,679 6,913,249

Selling,

general and

administrative 3,846,175 2,381,827 8,003,778 4,366,861

Total Operating

Expenses 12,808,789 6,541,230 25,447,773 11,431,856

LOSS FROM

OPERATIONS (11,374,570) (5,832,714) (22,208,036) (9,913,125)

Interest income 372,180
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
2. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
3. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
4. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
5. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
8. Halozyme Therapeutics Amends Stockholder Rights Plan
9. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
10. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
11. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... ... supplier, announces the launch of their 2nd generation cell therapy POD® design. The ... CT, but it also represents a new POD® design. , “G-CON first ...
(Date:7/29/2015)... July 29, 2015  Therapath Neuropathology ( www.Therapath.com ... partnerships with VA and Military Medical centers both ... Density (ENFD) and Sweat Gland Nerve Fiber Density ... ( https://therapath.com/skin ). Demonstration of ... (ENFD) on punch skin biopsy is a highly ...
(Date:7/29/2015)... July 29, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... medicine company, is pleased to announce that the final ... have been locked.  Prototypes for industrial and regulatory ... an application for CE mark clearance to market ... in 2016. (Photo: http://photos.prnewswire.com/prnh/20150729/248373 )  ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel, a nighttime-specific product that targets ... amount of sugars that are able to enter fat cells, inhibiting the formation ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3Neuropathology services for VA and Military health systems 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3
... N.Y. A new technique for growing single-crystal ... enable the development of smaller, more powerful heat ... , Researchers at Rensselaer Polytechnic Institute have discovered ... up of two single crystals using a biomolecular ...
... In conjunction with,CorVel Corporation,s (Nasdaq: CRVL ) quarterly earnings release, CorVel ... on Tuesday, August 5th at 11:30 am Eastern Time., Event: ... by: Dan Starck, President and CEO ... Date: 11:30 am Eastern Time, Tuesday, ...
... July 17 Researchers at Fred Hutchinson Cancer,Research ... from the,National Human Genome Research Institute to better ... The Hutchinson Center is one of,four U.S. research ... this effort., The Hutchinson Center project, led ...
Cached Biology Technology:'Nanosculpture' could enable new types of heat pumps and energy converters 2CorVel Corporation Announces Earnings Release Webcast 2Hutchinson Center Receives $7.6 Million Federal Grant to Study How Genetic Variations Influence Risk of Common Diseases 2Hutchinson Center Receives $7.6 Million Federal Grant to Study How Genetic Variations Influence Risk of Common Diseases 3
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. ... a biometric authentication company focused on the growing ... smart wallet, announces that it has filed provisional ... and Method. This invention highlights ... only authorizes an account, but also the user ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:7/8/2015)... NEW YORK , July 8, 2015  BD ... announced BD & Guidepoint Mentor, a new ... to Guidepoint,s expert network services. BD ... technologies to improve healthcare delivery and outcomes and, with ... start-up entrepreneur will be able to directly engage with ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... CA--A team of marine scientists has found that toxin-producing algae ... common in the open ocean, where the addition of iron ... the harmful algae. The new findings, reported this week in ... add to concerns about proposals to use iron fertilization of ...
... Medicine researchers at the Robert H. Lurie Comprehensive Cancer Center ... made from a chemical in soy could prevent the movement ... the body. These findings will be presented at the ... Prevention Research Conference. Genistein, a natural chemical found in ...
... 8, 2010 A study published in the November ... the Alzheimer,s Association suggests that taking docosahexaenoic acid ... with mild cognitive impairments. This is promising news ... to maintain memory and support overall cognitive health. The ...
Cached Biology News:Iron stimulates blooms of toxin-producing algae in open ocean, study finds 2Soy may stop prostate cancer spread 2DHA improves memory and cognitive function in older adults 2
Fetal Calf Serum Replacement (Bistec) serum...
NEWBORN CALF SERUM AND PLASMA...
... reagent for Virus isolation ... unique water insoluble Elastomeric ... and chaotropes; Engineered to ... viruses while preserving infectivity; ...
Mouse monoclonal [Ley 37D/G6] to LKB1 ( Abpromise for all tested applications). entrezGeneID: 6794 SwissProtID: Q15831...
Biology Products: